Commentary

Richard G. Bach

doi:10.7326/J22-0002

Commentary

Richard G. Bach

Research output: Contribution to journal › Comment/debate

1 Scopus citations

Abstract

SOURCE CITATION: Kim CJ, Park MW, Kim MC, et al. Unguided de-escalation from ticagrelor to clopidogrel in stabilised patients with acute myocardial infarction undergoing percutaneous coronary intervention (TALOS-AMI): an investigator-initiated, open-label, multicentre, non-inferiority, randomised trial. Lancet. 2021;398:1305-16. 34627490.

Original language	English
Pages (from-to)	JC27
Journal	Annals of internal medicine
Volume	175
Issue number	3
DOIs	https://doi.org/10.7326/J22-0002
State	Published - Mar 1 2022

Access to Document

10.7326/J22-0002

Cite this

@article{08e48ba49bf7416086880b27d231bcd8,

title = "Commentary",

abstract = "SOURCE CITATION: Kim CJ, Park MW, Kim MC, et al. Unguided de-escalation from ticagrelor to clopidogrel in stabilised patients with acute myocardial infarction undergoing percutaneous coronary intervention (TALOS-AMI): an investigator-initiated, open-label, multicentre, non-inferiority, randomised trial. Lancet. 2021;398:1305-16. 34627490.",

author = "Bach, \{Richard G.\}",

year = "2022",

month = mar,

day = "1",

doi = "10.7326/J22-0002",

language = "English",

volume = "175",

pages = "JC27",

journal = "Annals of internal medicine",

issn = "0003-4819",

number = "3",

}

TY - JOUR

T1 - Commentary

AU - Bach, Richard G.

PY - 2022/3/1

Y1 - 2022/3/1

N2 - SOURCE CITATION: Kim CJ, Park MW, Kim MC, et al. Unguided de-escalation from ticagrelor to clopidogrel in stabilised patients with acute myocardial infarction undergoing percutaneous coronary intervention (TALOS-AMI): an investigator-initiated, open-label, multicentre, non-inferiority, randomised trial. Lancet. 2021;398:1305-16. 34627490.

AB - SOURCE CITATION: Kim CJ, Park MW, Kim MC, et al. Unguided de-escalation from ticagrelor to clopidogrel in stabilised patients with acute myocardial infarction undergoing percutaneous coronary intervention (TALOS-AMI): an investigator-initiated, open-label, multicentre, non-inferiority, randomised trial. Lancet. 2021;398:1305-16. 34627490.

UR - https://www.scopus.com/pages/publications/85126490256

U2 - 10.7326/J22-0002

DO - 10.7326/J22-0002

M3 - Comment/debate

C2 - 35226532

AN - SCOPUS:85126490256

SN - 0003-4819

VL - 175

SP - JC27

JO - Annals of internal medicine

JF - Annals of internal medicine

IS - 3

ER -

Commentary

Abstract

Access to Document

Other files and links

Fingerprint

Cite this